TY - JOUR T1 - The prevalence of olfactory dysfunction and its associated factors in patients with COVID-19 infection JF - medRxiv DO - 10.1101/2021.01.27.21250153 SP - 2021.01.27.21250153 AU - Md Mehedi Hasan AU - Naima Ahmed Tamanna AU - Mohammad Nasimul Jamal AU - Md Jamal Uddin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250153.abstract N2 - Objective To determine the prevalence of olfactory dysfunctions, mainly, anosmia and to identify its associated factors in patients with COVID-19 infection.Study design A hospital-based prospective observational cohort studySetting A COVID dedicated hospital, Square Hospitals Ltd., Dhaka, Bangladesh.Methods We collected patients’ information including laboratory-confirmed COVID-19 test results. We used Pearson Chi-square test and logistic regression model to assess the associations between demographic and clinical characteristics and olfactory outcomes.Results Out of 600 COVID-19 positive patients, 38.7% were diagnosed with olfactory dysfunction. Our analyses showed that patients’ age, smoking status, cough, dyspnea, sore throat, asthenia, and nausea or vomiting were significantly associated with the anosmia. We observed the risk of developing anosmia was greater in younger patients than in older patients, and this risk decreased as age increased [odds ratio (OR) range for different age groups: 1.26 to 1.08]. Smoking patients were 1.73 times more likely to experience anosmia than non-smoking patients [OR=1.73, 95% confidence interval (CI) = 1.01-2.98]. In addition, patients complained asthenia had a significantly double risk of developing the anosmia [OR = 1.96, CI = 1.23-3.06].Conclusions Our study shows that about 39% of patients diagnosed with olfactory dysfunction. Patients’ age, smoking status, and asthenia are significantly positively associated with the anosmia. Since anosmia can be a significant marker for the diagnosis of COVID-19, we suggest regular screening of olfactory dysfunction in patients with early symptoms of COVID-19, particularly younger patients, smoker, and complained asthenia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical clearance was taken from the ethical committee at SQUARE Hospital Ltd.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collected patients information including laboratory-confirmed COVID-19 test results from a COVID dedicated hospital, Square Hospitals Ltd., Dhaka, Bangladesh. ER -